We identified a cancer-specific differentially methylated region located in the ABI3 promoter, which is hypermethylated in thyroid cell lines and thyroid carcinoma samples while is hypomethylated in the benign samples (FTA) and in a non-thyroid cell model (melanoma cells). This evidence concerns the gene ABI3 and thyroid gland disorder.